Payment overview · 2025
General Payments
$153.15
18 reported records · 2 companies
Healthcare provider profile · identity verified
Robert Kirk Saucier, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BOSSIER CITY, LA · NPI 1659369411
Verified facts
What the public records show
CMS Open Payments records show Robert Kirk Saucier, M.D. received $153.15 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 89.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.70 | 89.9% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.45 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $153.15 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $137.70 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $137.70 | 17 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 212 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
212 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 790 | 219 |
| Amlodipine Besylate | Amlodipine Besylate | 531 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 513 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 500 | 139 |
| Lisinopril | Lisinopril | 426 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 418 | 121 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 366 | 52 |
| Tramadol Hcl | Tramadol Hcl | 356 | 71 |
| Gabapentin | Gabapentin | 326 | 88 |
| Trazodone Hcl | Trazodone Hcl | 320 | 80 |
| Losartan Potassium | Losartan Potassium | 303 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 86 |
| Furosemide | Furosemide | 272 | 84 |
| Alprazolam | Alprazolam | 265 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 73 |
| Montelukast Sodium | Montelukast Sodium | 247 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 59 |
| Meloxicam | Meloxicam | 236 | 65 |
| Metformin Hcl Er | Metformin Hcl | 231 | 61 |
| Omeprazole | Omeprazole | 227 | 66 |
| Clonazepam | Clonazepam | 222 | 41 |
| Potassium Chloride | Potassium Chloride | 222 | 69 |
| Mounjaro | Tirzepatide | 212 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 193 | 46 |
| Simvastatin | Simvastatin | 192 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 50 |
| Ozempic | Semaglutide | 187 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 54 |
| Metformin Hcl | Metformin Hcl | 169 | 52 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 167 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 163 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 158 | 55 |
| Ezetimibe | Ezetimibe | 155 | 34 |
| Prednisone | Prednisone | 151 | 113 |
| Glimepiride | Glimepiride | 135 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 29 |
| Celecoxib | Celecoxib | 128 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 34 |
| Eliquis | Apixaban | 121 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 37 |
| Sertraline Hcl | Sertraline Hcl | 121 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 31 |
| Spironolactone | Spironolactone | 111 | 30 |
| Pregabalin | Pregabalin | 110 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 109 | 37 |
| Temazepam | Temazepam | 107 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 30 |
| Allopurinol | Allopurinol | 104 | 27 |
| Valsartan | Valsartan | 102 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 27 |
| Carvedilol | Carvedilol | 94 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 94 | 11 |
| Jardiance | Empagliflozin | 93 | 27 |
| Buspirone Hcl | Buspirone Hcl | 92 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 17 |
| Januvia | Sitagliptin Phosphate | 75 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 11 |
| Bumetanide | Bumetanide | 71 | 23 |
| Azithromycin | Azithromycin | 70 | 58 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 62 |
| Nifedipine Er | Nifedipine | 69 | 19 |
| Estradiol | Estradiol | 68 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 66 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 54 |
| Valacyclovir | Valacyclovir Hcl | 62 | 25 |
| Diazepam | Diazepam | 61 | 13 |
| Fluconazole | Fluconazole | 61 | 42 |
| Tresiba Flextouch U-200 | Insulin Degludec | 61 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 60 | 15 |
| Donepezil Hcl | Donepezil Hcl | 58 | 24 |
| Linzess | Linaclotide | 58 | 18 |
| Lorazepam | Lorazepam | 58 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 17 |
| Alendronate Sodium | Alendronate Sodium | 52 | 16 |
| Finasteride | Finasteride | 51 | 18 |
| Mirtazapine | Mirtazapine | 51 | 17 |
| Synthroid | Levothyroxine Sodium | 50 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 49 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 32 |
| Atenolol | Atenolol | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 15 |
| Tradjenta | Linagliptin | 44 | 11 |
| Clonidine Hcl | Clonidine Hcl | 43 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 12 |
| Cefdinir | Cefdinir | 40 | 38 |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Glipizide | Glipizide | 40 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 12 |
| Doxepin Hcl | Doxepin Hcl | 39 | 12 |
| Famotidine | Famotidine | 38 | 19 |
| Ondansetron Odt | Ondansetron | 37 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Nystatin | Nystatin | 33 | 20 |
| Telmisartan | Telmisartan | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Ketoconazole | Ketoconazole | 18 | 12 |
| Promethazine Hcl | Promethazine Hcl | 18 | 11 |
| Humulin N | Insulin Nph Human Isophane | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Eplerenone | Eplerenone | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $153.15 · 18 records | ABBVIE INC. | MOUNJARO, QULIPTA, UBRELVY, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error